Never miss a post—subscribe below to get the latest updates and exclusive content delivered straight to your inbox.
Apr 28, 2026
WeightWatchers filed for bankruptcy in May 2025. It came back as a telehealth platform that prescribes Ozempic, Wegovy, Zepbound, and now Foundayo. Its board includes the man who launched Mounjaro for Eli Lilly. The CEO who built the pivot left last month. The 12-month subscription contract that comes with all of it has not moved.
Apr 27, 2026
Lilly's new oral GLP-1 pill launched April 1. The marketing leads with "take it any time, with or without food." The package insert tells a different story for women on the pill. We walk through what's actually in there, why it likely contributed to the slow launch Wall Street covered all weekend, and what it means if you were considering Foundayo for weight loss.
Apr 26, 2026
Yesterday Off Label introduced Dr. David Kim. Today we teach you to read his papers (and any cost-effectiveness study) the way the policy world reads them. The same drug. Four studies. Four wildly different answers. Six things to check. Once you can do this, you stop being intimidated by citations and start being able to push back on insurance denials with the right framing.
Apr 25, 2026
Dr. David Kim cold-emailed Harvard as a student. He's now a UChicago health economist whose three peer-reviewed papers built the academic case that GLP-1s aren't cost-effective at lifetime use prices. The federal government walked away from Medicare Part D expansion 4 days ago. Kim's framework just got validated in real time.
Apr 24, 2026
Why "you have to take this forever" is positioning, not consensus. UK NICE has a 2-year cap. Real-world data shows fewer than 1 in 4 patients stay on a GLP-1 after 1 year. The cost-effectiveness studies say current prices fail at lifetime use. The federal government just delayed Medicare expansion. The evidence is shifting. The marketing hasn't.
The evidence-based playbook for stopping a GLP-1 without the 60% average weight regain. Slow taper. Protein floor. Generic bridge meds. Clear restart triggers. The protocol based on the newest 2026 data your doctor may not have walked you through.
